PL3019532T3 - Ludzkie bispecyficzne cząsteczki angażujące przeciwciało egfrviii - Google Patents

Ludzkie bispecyficzne cząsteczki angażujące przeciwciało egfrviii

Info

Publication number
PL3019532T3
PL3019532T3 PL14823231T PL14823231T PL3019532T3 PL 3019532 T3 PL3019532 T3 PL 3019532T3 PL 14823231 T PL14823231 T PL 14823231T PL 14823231 T PL14823231 T PL 14823231T PL 3019532 T3 PL3019532 T3 PL 3019532T3
Authority
PL
Poland
Prior art keywords
egfrviii antibody
human bispecific
engaging molecules
antibody engaging
bispecific egfrviii
Prior art date
Application number
PL14823231T
Other languages
English (en)
Inventor
Darell D Bigner
John SAMPSON
Chien-Tsun Kuan
Mingqing Cai
Bryan D Choi
Patrick C Gedeon
Ira H Pastan
Original Assignee
Univ Duke
The Government Of The United States As Represented By The Secretary Of The Dept Of Health And Human
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, The Government Of The United States As Represented By The Secretary Of The Dept Of Health And Human filed Critical Univ Duke
Publication of PL3019532T3 publication Critical patent/PL3019532T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14823231T 2013-07-09 2014-07-09 Ludzkie bispecyficzne cząsteczki angażujące przeciwciało egfrviii PL3019532T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844119P 2013-07-09 2013-07-09
EP14823231.7A EP3019532B1 (en) 2013-07-09 2014-07-09 Human bispecific egfrviii antibody engaging molecules
PCT/US2014/046003 WO2015006482A1 (en) 2013-07-09 2014-07-09 CERTAIN IMPROVED HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES

Publications (1)

Publication Number Publication Date
PL3019532T3 true PL3019532T3 (pl) 2019-10-31

Family

ID=52280577

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14823231T PL3019532T3 (pl) 2013-07-09 2014-07-09 Ludzkie bispecyficzne cząsteczki angażujące przeciwciało egfrviii

Country Status (9)

Country Link
US (2) US10053514B2 (pl)
EP (1) EP3019532B1 (pl)
JP (1) JP6242484B2 (pl)
AU (1) AU2014287244B2 (pl)
CA (1) CA2917919C (pl)
ES (1) ES2718399T3 (pl)
PL (1) PL3019532T3 (pl)
TR (1) TR201904121T4 (pl)
WO (1) WO2015006482A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3405490B1 (en) * 2016-01-21 2021-10-20 Pfizer Inc. Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
EA201891641A1 (ru) 2016-01-21 2019-01-31 Пфайзер Инк. Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
TN2018000266A1 (en) 2016-02-03 2020-01-16 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
WO2018140845A2 (en) * 2017-01-27 2018-08-02 Duke University Bi-specific antibodies to cd64 and a disease antigen
AU2018347607B2 (en) 2017-10-14 2025-08-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2023133357A2 (en) * 2022-01-10 2023-07-13 Expression Therapeutics, Llc Engineered t cells
JP2025539364A (ja) * 2022-11-22 2025-12-05 エクスプレッション セラピューティクス， エルエルシー 遺伝子操作ｔ細胞
EP4648854A1 (en) * 2023-01-10 2025-11-19 Expression Therapeutics, LLC Engineered t cells
WO2025203029A1 (en) * 2024-03-28 2025-10-02 Hadasit Medical Research Services And Development Ltd. Tricer - a tri-specific cell engager and retainer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235097A (en) 1979-03-27 1980-11-25 E. I. Du Pont De Nemours And Company Dosimeter for measuring gaseous contaminants
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
AU639726B2 (en) 1989-09-08 1993-08-05 Duke University Structural alterations of the egf receptor gene in human gliomas
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
DK1071752T3 (da) * 1998-04-21 2003-10-20 Micromet Ag CD19xCD3-specifikke polypeptider og anvendelsen deraf
CA2530172A1 (en) * 2003-06-27 2005-02-10 Abgenix, Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
JP4974812B2 (ja) 2007-08-27 2012-07-11 三洋電機株式会社 電子カメラ
US9249217B2 (en) * 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
EP2861619A4 (en) * 2012-06-07 2016-01-27 Univ Duke HUMAN BISPECIFIC ANTIBODY MOLECULAR EGFRVII

Also Published As

Publication number Publication date
US20180362659A1 (en) 2018-12-20
WO2015006482A1 (en) 2015-01-15
EP3019532A1 (en) 2016-05-18
EP3019532A4 (en) 2017-03-15
JP6242484B2 (ja) 2017-12-06
AU2014287244A1 (en) 2016-02-04
AU2014287244B2 (en) 2017-06-15
CA2917919C (en) 2019-07-02
CA2917919A1 (en) 2015-01-15
US10053514B2 (en) 2018-08-21
JP2016523562A (ja) 2016-08-12
US20160168263A1 (en) 2016-06-16
TR201904121T4 (tr) 2019-04-22
ES2718399T3 (es) 2019-07-01
EP3019532B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
IL271102A (en) Antigen-binding molecules from bispecific t-cell activators
TWI563003B (en) Human anti-il-33 neutralization monoclonal antibody
PL3019532T3 (pl) Ludzkie bispecyficzne cząsteczki angażujące przeciwciało egfrviii
GB201311487D0 (en) Bispecific molecules
AP2015008773A0 (en) Bispecific bivalent scfv-fc molecules
GB201319161D0 (en) Multivalent antigen-binding protein molecules
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
SG11201510653YA (en) Anti-fcrh5 antibodies
GB201322583D0 (en) Antibodies
SI3480215T1 (sl) Protitelo proti-HER2 in njegov konjugat
IL244043A0 (en) Antibodies
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
IL240440A0 (en) Antibodies against her2 with a high level of galactosylation and their uses
GB201300706D0 (en) Antibody
IL245488B (en) Anti- ccl17 antibodies
SI3016977T1 (sl) Humana protitelesa proti IL-32
GB201302878D0 (en) Modified igG molecules
GB201318283D0 (en) Antibodies